newsmetry
rusign inget started
macro

Truist keeps Biogen at Buy and raises price target to $260

Truist Securities kept its Buy rating on Biogen shares and lifted its price target from $235 to $260, according to TradingView data.

published on Newsmetry
original source published

the same feed is available to bots and dashboards through the api. connect the api →

Newsmetry newsroom

what happened

Truist Securities kept its Buy rating on Biogen and raised its price target by 10.6%, from $235 to $260, according to TradingView. The new target implies about 6.5% upside from the October 28 close of $244.05.

Across the five most recent analyst notes over the past 30 days, targets range from $230 to $290. Baird and Needham sit at $290, Barclays is at $230 with an Equal-Weight rating, B of A Securities is at $244 with Neutral, and TD Cowen is at $250.

why it matters

Single analyst updates rarely move a large biotech on their own, but they show how Wall Street views the stock's outlook. Investors usually watch quarterly results and pipeline news more closely. This is informational and not investment advice.

tags

Analyst RatingStockUnited StatesDenmark

instruments

Biogen

sources

  1. Truist Securities maintains Biogen at Buy, raises price target to $260 from $235 — TradingView, 29 October 2026 at 14:36 UTC
  2. Truist Securities maintains Axogen at Buy, raises price target to $60 from $53 — TradingView, 29 October 2026 at 14:35 UTC
  3. Truist Securities maintains Expand Energy at Buy, raises price target to $122 from $120 — TradingView, 29 October 2026 at 14:54 UTC
  4. Truist Securities maintains Glaukos at Buy, raises price target to $255 from $215 — TradingView, 29 October 2026 at 15:01 UTC
  5. Truist Securities maintains Genmab at Buy, raises price target to $67 from $45 — TradingView, 29 October 2026 at 14:59 UTC
  6. Truist Securities maintains Labcorp Holdings at Buy, raises price target to $395 from $365 — TradingView, 29 October 2026 at 15:08 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗

related stories